David M. Salerno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David M. Salerno has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Hedvat
NewYork‐Presbyterian Hospital Department of Pharmacy New York New York USA
13 shared publications - Nicholas W. Lange
NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
12 shared publications - Justin K. Chen
Department of Pharmacy Children's Healthcare of Atlanta Atlanta Georgia USA
7 shared publications - Douglas L. Jennings
Thomas J. Long School of Pharmacy University of the Pacific Sacramento California USA
5 shared publications Jenna Scheffert
Department of Pharmacy New York Presbyterian Hospital New York New York USA
5 shared publications- Marcus R. Pereira
Division of Infectious Diseases Department of Medicine Columbia University Irving Medical Center New York City New York USA
5 shared publications
Latest Publications
- 18 February 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (2) , e70111
Liver Transplant Fast‐Track With an Emphasis on Reduced Delirium: A Multidisciplinary Approach to Reducing Length of Stay
Enhanced recovery after surgery protocols have been shown to reduce length of stay in transplant patients. The purpose of our study was to evaluate the impact of a standardized protocol in liver transplant recipients (LTR) on length of stay (LOS) and delirium during the index hospitalization post‐LT. Elements of the protocol included reduced intraoperative corticosteroids (from methylprednisolone 1000 to 250 mg), conversion of steroid taper to be administered once‐daily instead of BID, optimal end‐of‐case intraoperative extubation, multimodal analgesia, early removal of surgical drains, implementation of dietary and physical therapy plans and education for multidisciplinary providers and patients about expected LOS. The primary outcome was post‐LT LOS. Secondary outcomes included incidence of delirium, ICU LOS, rejection at 60 days and readmission within 30 days of discharge. A total of 125 LTRs were included. Baseline characteristics were similar between groups. The median LOS was 12 days (IQR, 9–19) and 10 days (IQR, 8–15) in the pre‐ and post‐implementation groups, respectively (p = 0.025). ICU LOS was 2.9 (IQR, 2.1–4) and 2.7 (IQR, 1.9–3.7) in the pre‐ and post‐implementation groups, respectively (p = 0.525). In the pre‐ and post‐implementation groups, the incidence of delirium was 17 (25.8%) and 5 (8.6%), respectively (p = 0.013). The incidence of treated rejection at 60 days was 3% (0.0–10.1) and 5.2% (2.9–15.2) in the pre‐ and post‐implementation groups, respectively (p = 0.550). Implementation of a Fast Track protocol in a high acuity LTR was feasible and safe and was associated with a reduction in LOS.
- 18 February 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (2) , e70111
Liver Transplant Fast‐Track With an Emphasis on Reduced Delirium: A Multidisciplinary Approach to Reducing Length of Stay
Enhanced recovery after surgery protocols have been shown to reduce length of stay in transplant patients. The purpose of our study was to evaluate the impact of a standardized protocol in liver transplant recipients (LTR) on length of stay (LOS) and delirium during the index hospitalization post‐LT. Elements of the protocol included reduced intraoperative corticosteroids (from methylprednisolone 1000 to 250 mg), conversion of steroid taper to be administered once‐daily instead of BID, optimal end‐of‐case intraoperative extubation, multimodal analgesia, early removal of surgical drains, implementation of dietary and physical therapy plans and education for multidisciplinary providers and patients about expected LOS. The primary outcome was post‐LT LOS. Secondary outcomes included incidence of delirium, ICU LOS, rejection at 60 days and readmission within 30 days of discharge. A total of 125 LTRs were included. Baseline characteristics were similar between groups. The median LOS was 12 days (IQR, 9–19) and 10 days (IQR, 8–15) in the pre‐ and post‐implementation groups, respectively (p = 0.025). ICU LOS was 2.9 (IQR, 2.1–4) and 2.7 (IQR, 1.9–3.7) in the pre‐ and post‐implementation groups, respectively (p = 0.525). In the pre‐ and post‐implementation groups, the incidence of delirium was 17 (25.8%) and 5 (8.6%), respectively (p = 0.013). The incidence of treated rejection at 60 days was 3% (0.0–10.1) and 5.2% (2.9–15.2) in the pre‐ and post‐implementation groups, respectively (p = 0.550). Implementation of a Fast Track protocol in a high acuity LTR was feasible and safe and was associated with a reduction in LOS.
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 27 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , e62-e63
Pre-transplant immune checkpoint inhibitor use: The intersection between medicine, surgery and pharmacy
- 27 July 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , e62-e63
Pre-transplant immune checkpoint inhibitor use: The intersection between medicine, surgery and pharmacy
- 19 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15278
Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients
- 19 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15278
Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients
- Open Access
- 21 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1027-1034
Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
- 21 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1027-1034
Open AccessObesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
- 14 August 2023
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 65 (1) , 113-115
Successful Continuation of Clozapine Treatment During Liver Transplantation: Case Report
- 14 August 2023
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 65 (1) , 113-115
Successful Continuation of Clozapine Treatment During Liver Transplantation: Case Report
- 22 May 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (11) , e468-e469
Anticoagulation Stability With Bivalirudin: Positioning the Horse Before the Cart
- 22 May 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (11) , e468-e469
Anticoagulation Stability With Bivalirudin: Positioning the Horse Before the Cart
- 20 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , e205-e211
Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.
- 20 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , e205-e211
Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.
- 15 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14929
Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients
- 15 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14929
Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
Open AccessCOVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era